40 results about "Intramuscular route" patented technology

The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.

The invention provides a method for preventing formation of inhibitors to blood coagulation factor VIII or factor IX in a subject having haemophilia, the method comprising administering (via intravenous, subcutaneous, intradermal, or intramuscular routes) to a previously untreated subject an effective dosage of factor VIIa or a factor VII-related polypeptide.

The present invention relates to methods and devices for administration of vaccines and therapeutic agents into the intradermal layer of the skin. The methods of the present invention elicit increased humoral and/or cellular response as compared to conventional vaccine delivery methods, e.g., intramuscular route. Furthermore, the methods of the present invention facilitate induction of an immune response by an amount of vaccine which is otherwise insufficient for inducing an immune response when delivered via conventional vaccine routes, e.g., intramuscular route.

The invention discloses a slow-release microsphere preparation containing a recombined human haemopoietin. The slow-release microsphere preparation is prepared by the S/O/W compound emulsion solvent volatilization method. The preparation method comprises that: firstly, by the freeze-drying method, a micro particle containing the human serum albumin and the recombined human haemopoietin is prepared; secondly, by using a biodegradable high molecular material of lactic acid-glycollic acid block copolymer as a carrier material, the micro particle containing the human serum albumin and the recombined human haemopoietin is encapsulated; and thirdly, the lactic acid-glycollic acid block copolymer slow-release microsphere preparation containing the recombined human haemopoietin is prepared. The microsphere of the invention has the advantages of smooth surface, uniform appearance, regular size and no adhesion, the average particle size is between 70 and 105mu m; moreover, the microsphere is high in drug-carrying quantity and encapsulating rate, and the in vitro slow release period is more than 30 days. The obtained slow-release microsphere preparation is good in biocompatibility and can be used for non-intravenous drug administration such as hypodermic drug administration and intramuscular drug administration, and when used as a drug preparation for treating renal anemia, the slow-release microsphere preparation can improve the hematocrit of a patient.

The invention relates to a formula of a sartan compound or a pharmaceutically acceptable salt thereof and a calcium channel blocker or a pharmaceutically acceptable salt, which belong to the technical field of medicine. The formula comprises the following components by weight proportion: 5-200 parts of [(2-n-propyl-4-methyl-1H-benzimidazole)-6-carboxamide-1-radical] methyl biphenyl tetrazolium and a carboxylic acid compound and salt thereof and 0.5-60 parts of a calcium ion retarder; the preferable scheme is 20-100 parts of the [(2-n-propyl-4-methyl-1H-benzimidazole)-6-carboxamide-1-radical] methyl biphenyl tetrazolium and the carboxylic acid compound and the salt thereof and 1-30 parts of the calcium ion retarder; the administration forms can be one of the following forms such as oral administration, inhalation, subcutaneous administration, sublingual administration, intramuscular administration, intravenous administration, transdermal administration, local administration or rectal administration. In the formula of the invention, an antihypertensive I and the calcium channel blocker or the pharmaceutically acceptable salt are studied; thus a preparation with a new formula for treating hypertension is provided. The preparation is characterized by low dosage, obvious blood pressure lowering effect and little adverse reaction.

Preparations to be administered for treating or preventing ischemic diseases or arterial diseases which contain Hepatocyte growth factor (HGF) as an active ingredient. The preparations provide such effect that HGF concentration in an affected region to which HGF was administered is maintained, a half-life is longer, a dose can be reduced, and other organs except the affected region are less affected in comparison with intravenous administration.

The invention provides a Chinese traditional medicine compound prescription, and a preparation method and the purpose thereof, which mainly provides the Chinese traditional medicine compound prescription consisting of evodia, marsdenia tenacissima, climbing nightshade, oriental biter weed, Chinese fevervine, spatholobus stem, honey-suckle stem, wild grapevine, sargentg loryvine, Radix sophora flavescens, Paris Rhizome, licorice, etc. The preparation method comprisesthe following steps: step one, the alcohol reflux or the warm immersion abstraction of the evodia and the climbing nightshade, step two, the water extract-ethanol precipitation of gruffs and the rest medicinal materials, and step three, the blending of aqueous extract and ethanol extract. The invention provides the purposes of the compound prescription and the extract for the medicines of curing lung cancer, liver cancer, stomach cancer, rectal cancer, oophoroma, cervical carcinoma, prostatic cancer, bone cancer and other cancers, and simultaneously the invention also provides all administration forms including oral administration, rectum administration, intramuscular administration, vena administration, nasal cavity administration, vagina administration, subcutaneous administration, etc., and all preparation forms accepted by pellet, hard capsule, soft capsule, granula, oral liquid, syrup and pharmacy.

The present invention provides a flavonol compound and a bioactive extract/fraction from Ulmus wallichiana useful for the management or prevention or treatment of bone disorders. Said extract/fraction comprising marker compounds of general formula 2, K058: R₁═R₂═0H K012: R₁═R₂═OH, 2,3 double bond K068: R₁═R₂═H KIOOi R₁═OH, R₂═H mula 2 Wherein the marker compounds K012, K058, K068, K100 ranges 6.7-12%, 1.7-4.5%, 0.6-1.2%, 1.7-4.5% respectively in alcoholic extract and a process of extraction thereof. According to another aspect of the invention provides a pharmaceutical composition comprising the said compound. The present invention further provides a method of treating bone disorders by administering the pharmaceutical composition by oral, intravenous, subcutaneous, intra-peritoneal or intramuscular route.

The invention relates to the technical field of medicines and in particular relates to a novel natural drug which is extracted and separated from Chinese Dictyopteris undulate Holmes and has an antitumor effect. The drug is a steroidal compound dictyopterisin G. An in-vitro antitumor activity test shows that the IC50 values of the compound to a human acute promyelocytic leukemic cell (HL-60) and ahuman lung cancer cell (A-549) are respectively 2.70mu M and 2.01mu M, and therefore, the compound can be used for preparing an antitumor drug, can be prepared into an antitumor drug composition together with other drugs and can be prepared into dosage forms such as an injection, a tablet, a pill, a capsule, a solution, a suspension agent and an emulsion together with pharmaceutically acceptableauxiliary materials; and the administration route can be oral administration, intravenous administration, intramuscular administration or transdermal administration.

The invention relates to a composite nanoparticle preparation for injection administration for treatment of tumors, in particular to compound palmitoyl ascorbic acid ester and docetaxel composite nanoparticles and a preparation method thereof. Through combination of palmitoyl ascorbic acid ester and docetaxel, it is found through in-vitro and in-vivo experiments that the composite nanoparticles can remarkably enhance the anti-tumor efficacy of docetaxel, and docetaxel can achieve the efficacy at an extremely-low dose. Through intravenous administration, artery administration, intramuscular administration, subcutaneous administration, intraperitoneal administration and other administration modes, especially interventional administration such as intravenous injection and intratumoral injection, the effectiveness and safety of clinical application of docetaxel are improved. The adopted preparation method is simple in process and low in cost. The prepared nanoparticles are uniform in particle size, high in encapsulation rate and good in drug release property. Compared with palmitoyl ascorbic acid ester nanoparticles or docetaxel single-recipe nanoparticles, the effects of inhibiting tumor cell growth in vitro and resisting tumor proliferation in vivo of the compound are enhanced remarkably.

The invention relates to an antibacterial and anti-virus injection and belongs to the field of biomedicines. A main component of the medicine is inactivated probiotic bacillus which is obtained by inactivating living probiotic bacillus. Inactivated probiotic bacillus intramuscular administration has antibacterial and anti-virus effects, can be used for prevention, treatment or adjuvant treatment of various bacterial diseases and virus diseases of human or animals and has a wide application prospect.

The invention relates to the technical field of medicines, and relates to a novel natural medicine having anti-tumor functions and extracted and separated from dictyopteris undulata Holmes in China. The medicine is a steroid compound that is dictyopterisin F. In-vitro anti-tumor activity tests prove that IC50 values of the compound for human acute promyelocytic leukemia cells (HL-60) and human lung cancer cells (A-549) are 2.45 [mu]M and 2.85 [mu]M respectively, and therefore the compound can be used for preparing anti-tumor medicines, can be prepared into anti-tumor medicine compositions withother medicines, and can be prepared into injections, tablets, pills, capsules, solutions, suspensions, emulsions, and other dosage forms with pharmaceutically acceptable auxiliary materials, and administration routes of the compound can be oral administration, intravenous administration, intramuscular administration or percutaneous administration.

Provided herein are methods for using compositions that include a fusion protein having a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. In one embodiment the composition is used to confer immunity to plague, such as pneumonic plague, caused by Yersinia pestis. In one embodiment, the composition is administered to a mucosal surface, such as by an intranasal route. In one embodiment, the administration to a mucosal surface includes a vector that has a polynucleotide encoding a fusion protein, where the fusion protein includes a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. The administration is followed by a second administration by a different route, such as an intramuscular route. The second administration includes a fusion protein having the same three domains, and in one embodiment the fusion protein is the same one administered to a mucosal surface.

Disclosed herein are injectable compositions containing high concentration of paracetamol or its pharmaceutically acceptable salts wherein the concentration of paracetamol or its pharmaceutically acceptable salt is >150 mg/ml in a judiciously tailored solvent system comprising glycofurol, ethanol, water or a solvent system comprising glycofurol, ethanol, polyethylene glycol, water. The viscosity of the said injectables is <28 cps. Further disclosed is the process for preparing the said injectables. The injectables can be administered by intramuscular route, intravenous route or as intravenous infusion after diluting in one of the routinely used intravenous fluids, infusion solutions of antibacterial, antifungal and amoebicidal drugs and along with anxiolytics (Midazolam injection) or narcotic analgesics (Fentanyl Citrate injection etc) as they remain stable, clear and transparent at least for 6 hours after dilution.

The invention relates to the technical field of medicines and in particular relates to a novel natural drug which is extracted and separated from Chinese Dictyopteris undulate Holmes and has an antitumor effect. The drug is a steroidal compound dictyopterisin I. An in-vitro antitumor activity test shows that the IC50 values of the compound to a human acute promyelocytic leukemic cell (HL-60) and ahuman lung cancer cell (A-549) are respectively 1.26mu M and 1.35mu M, and therefore, the compound can be used for preparing an antitumor drug, can be prepared into an antitumor drug composition together with other drugs and can be prepared into dosage forms such as an injection, a tablet, a pill, a capsule, a solution, a suspension agent and an emulsion together with pharmaceutically acceptableauxiliary materials; and the administration route can be oral administration, intravenous administration, intramuscular administration or transdermal administration.

The invention discloses a composition lipidosome preparation used for parenteral administration tumor treatment. The composition lipidosome preparation comprises following ingredients: paclitaxel, L-palmitoyl ascorbate, a phospholipid substance, and a cholesterol analogue. According to a preparation method, L-palmitoyl ascorbate and paclitaxel are combined, the particle size of the obtained lipidosome is uniform, encapsulation efficiency is high, and drug releasing properties are excellent. It is found via in vivo and in vitro experiments that anti-tumor effect of paclitaxel is improved obviously; drug effect of paclitaxel can be achieved at a relatively low dosage; drug administration is realized via intravenous administration, artery administration, intramuscular administration, subcutaneous administration, intraperitoneal administration, and the like; and especially, clinical application availability and safety of paclitaxel are improved via interventional administration methods such as intravenous injection or intratumor injection.